Episode Details

On our latest Small Cap Sunday podcast, we shift our attention to the psychedelics space to do a deep dive into industry leader Cybin (NYSE: CYBN). Cybin Inc., a leading psychedelic company, has had an eventful 2024. With partnerships with top research institutions, expansion of Phase 2 trials, and innovative drug formulations, Cybin is making strides in mental health therapeutics. Their current focus includes the Phase 3 PARADIGM™ program CYB003’for treating Major Depressive Disorder, a substantial market opportunity. The company's strong financial position, with a cash reserve of C$209 million and C$285 million raised over the past year, supports its upcoming trials. Challenges such as regulatory hurdles and market volatility persist, but strategic partnerships and upcoming Phase 3 trials position Cybin for a promising 2025. Investors are hoping for regulation and further research announcements from the government that will equate to growth as the psychedelic industry continues to evolve. #MentalHealthAwareness #MentalHealthMatters #Psychedelics #PsychedelicResearch #PsychedelicTherapy #PsychedelicCommunity #PsychedelicScience Want to watch more videos about Small Cap Stocks?    • Bitcoin Surpasses $100K: Unprecedente...     • How Psychedelic Companies Attract Ana...     • Trade to Black I Small Cap Sunday - F...   Want to be updated on Cannabis, Small Cap, AI, and Crypto? Subscribe to our Daily Baked in Newsletter! https://newsletter.thedalesreport.com... Find us as well on Facebook, Twitter, Instagram, LinkedIn and on the Web: Facebook:   / thedalesreport   Twitter:   / thedalesreport   Instagram:

Listen Now